Anticancer Activity of Biotin Polyoxomolybdate Bioconjugate
Objectives: Polyoxometalates (POMs), polyanionic metal clusters, have been well recognized for their anticancer activity in recent decades. Despite their potential anticancer activity, normal cell toxicity is one of the pressing issues that prevent their further clinical applications. In this work, we synthesized a new bio-conjugate based on POM and biotin. We used biotin as a bio-molecule to control the cytotoxicity of POM on healthy cells and simultaneously increase the toxicity on cancerous cells. Methods: We synthesized the biotin derivative of POM via an amidation between the two molecules of biotin and amine groups on polyoxomolybdate. We approved the final structure using different spectroscopic data. We studied the cytotoxicity activity in-vitro using MTT protocol. We chose breast carcinoma cells (MCF-7) and hepatocellular carcinoma cells (HepG2) in comparison to the human umbilical vein endothelial cell (HUVEC). Results: Results showed that biotin could improve the anticancer activity of polyoxomoybdate (IC50; 0.082 mM) on MCF-7 and (IC50; 0.091 mM) on HepG2 cells. Furthermore, the biotin-polyoxomolybdate conjugate showed lower toxicity on healthy cells versus the parent polyoxomolybdate and the Cis-platin as an approved drug. Conclusion: Thus, we introduce promising novel POM bioconjugate, which can be further assessed in pre-clinical studies
1.WHO. Cancer-Key facts 12 September 2018 [Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
2. Chen H, Krans B. What Is Chemotherapy? March 1, 2016 [Available from: https://www.healthline.com/health/chemotherapy.
3. Wang SS, Yang GY. Recent advances in polyoxometalate-catalyzed reactions. Chem Rev 2015;115:4893–962. [CrossRef]
4. Jiao YQ, Zang HY, Wang XL, Zhou EL, Song BQ, Wang CG, et al. Self-assembled arrays of polyoxometalate-based metal– organic nanotubes for proton conduction and magnetism. Chem Commun 2015;51:11313–6. [CrossRef]
5. Santoni MP, Hanan GS, Hasenknopf B. Covalent multi-component systems of polyoxometalates and metal complexes: Toward multi-functional organic–inorganic hybrids in molecular and material sciences. Coordination Chem Rev 2014;281:64– 85. [CrossRef]
6. Yang FC, Wu KH, Lin WP, Hu MK. Preparation and antibacterial efficacy of bamboo charcoal/polyoxometalate biological protective material. Micropor Mesopor Mat 2009;118:467–72.
7. Zhang ZM, Duan X, Yao S, Wang Z, Lin Z, Li YG, et al. Cationmediated optical resolution and anticancer activity of chiral polyoxometalates built from entirely achiral building blocks. Chem Sci 2016;7:4220–9. [CrossRef] 8. Yamase T, Fujita H, Fukushima K. Medical chemistry of polyoxometalates. Part 1. Potent antitumor activity of polyoxomolybdates on animal transplantable tumors and human cancer xenograft. Inorg Chim Acta 1988;151:15–8. [CrossRef]
9. Boulmier A, Feng X, Oms O, Mialane P, Rivière E, Shin CJ, et al. Anticancer activity of polyoxometalate-bisphosphonate complexes: Synthesis, characterization, in vitro and in vivo results. Inorg Chem 2017;56:7558–65. [CrossRef]
10. Ogata A, Yanagie H, Ishikawa E, Morishita Y, Mitsui S, Yamashita A, et al. Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models. Br J Cancer 2008;98:399. [CrossRef]
11. Wu Q, Wang J, Zhang L, Hong A, Ren J. Molecular recognition of basic fibroblast growth factor by polyoxometalates. Ang Chem 2005;117:4116–20. [CrossRef]
12. Yamase T. Anti-tumor, -viral, and-bacterial activities of polyoxometalates for realizing an inorganic drug. J Mat Chem 2005;15:4773–82. [CrossRef]
13. Fu L, Gao H, Yan M, Li S, Li X, Dai Z, et al. Polyoxometalate‐ Based Organic–Inorganic Hybrids as Antitumor Drugs. Small 2015;11:2938–45. [CrossRef]
14. Dolbecq A, Dumas E, Mayer CR, Mialane P. Hybrid organic-inorganic polyoxometalate compounds: from structural diversity to applications. Chem Rev 2010;110:6009–48. [CrossRef]
15. Linnenberg O, Kondinski A, Stocker C, Monakhov KY. The Cu(i)- catalysed Huisgen 1,3-dipolar cycloaddition route to (bio-) organic functionalisation of polyoxovanadates. Dalton Trans (Cambridge, England : 2003). 2017;46:15636–40. [CrossRef]
16. Ventura D, Calderan A, Honisch C, Krol S, Serratì S, Bonchio M, et al. Synthesis and biological activity of an A nderson polyoxometalate bis‐functionalized with a B ombesin‐analog peptide. Peptide Sci 2018;110:e24047. [CrossRef]
17. Prudent R, Moucadel V, Laudet B, Barette C, Lafanechère L, Hasenknopf B, et al. Identification of Polyoxometalates as Nanomolar Noncompetitive Inhibitors of Protein Kinase CK2. ChemBiol 2008;15:683–92. [CrossRef]
18. Depeint F, Bruce WR, Shangari N, Mehta R, O’Brien PJ, Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. ChemBiol Inter 2006;163:94–112. [CrossRef]
19. Hu W, Fang L, Hua W, Gou S. Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance. JInorg Biochem 2017;175:47–57. [CrossRef]
20. Maiti S, Park N, Han JH, Jeon HM, Lee JH, Bhuniya S, et al. Gemcitabine–coumarin–biotin conjugates: a target specific theranostic anticancer prodrug. J Am Chem Soc 2013;135:4567– 72. [CrossRef]
21. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Rel 2009;136:21– 9. [CrossRef]
22. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomat 2010;31:358–65. [CrossRef]
23. YoungáKim W, SeungáKim J. Biotin-guided anticancer drug delivery with acidity-triggered drug release. Chem Commun 2015;51:9343–5. [CrossRef]
24. Plazuk D, Zakrzewski J, Salmain M, Błauż A, Rychlik B, Strzelczyk P, et al. Ferrocene–biotin conjugates targeting cancer cells: Synthesis, interaction with avidin, cytotoxic properties and the crystal structure of the complex of avidin with a biotin–linker–ferrocene conjugate. Organometal 2013;32:5774– 83. [CrossRef]
25. Ren WX, Han J, Uhm S, Jang YJ, Kang C, Kim JH, et al. Recent development of biotin conjugation in biological imaging, sensing, and target delivery. Chem Commun 2015;51:10403– 18. [CrossRef]
26. Chen S, Zhao X, Chen J, Chen J, Kuznetsova L, Wong SS, et al. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem 2010;21:979–87. [CrossRef]
27. Ginsberg AP. Inorganic syntheses: John Wiley & Sons; 1990.
28. Marcoux PR, Hasenknopf B, Vaissermann J, Gouzerh P. Developing remote metal binding sites in heteropolymolybdates. Eur J Inorg Chem 2003;2003:2406–12. [CrossRef]
29. Vashist SK. Comparison of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide based strategies to crosslink antibodies on amine-functionalized platforms for immunodiagnostic applications. Diagnos 2012;2:23–33. [CrossRef]
30. Freshney RI. Culture of specific cell types. Culture of animal cells: a manual of basic technique. 2005. [CrossRef]
31. Yang HK, Cheng YX, Su MM, Xiao Y, Hu MB, Wang W, et al. Polyoxometalate–biomolecule conjugates: A new approach to create hybrid drugs for cancer therapeutics. BioorgMed Chem Lett 2013;23:1462–6. [CrossRef]
32. Bijelic A, Aureliano M, Rompel A. Polyoxometalates as potential next‐generation metallodrugs in the combat against cancer. Ang Chem Int Ed 2019;58:2980–99. [CrossRef]
33. Stephan H, Kubeil M, Emmerling F, Müller CE. Polyoxometalates as Versatile Enzyme Inhibitors. Eur J Inorg Chem 2013;2013:1585–94. [CrossRef]
34. https://www.proteinatlas.org/ENSG00000159267-HLCS
35. Zamolo VA, Modugno G, Lubian E, Cazzolaro A, Mancin F, Giotta L, et al. Selective Targeting of Proteins by Hybrid Polyoxometalates: Interaction Between a Bis-Biotinylated Hybrid Conjugate and Avidin. Front Chem 2018;6:278. [CrossRef]